Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daraxonrasib in Recurrent KRAS-Mutant Biliary Tract Cancer
NCT07793253Phase 2Not yet recruiting
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Nov 2026
- Primary completion
- Nov 2030
- Countries
- 1
01
Overview
A Phase 2 trial of daraxonrasib in biliary tract cancer (BTC), sponsored by Sidney Kimmel Comprehensive Cancer Center. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
daraxonrasib
03
Conditions
biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT07793253.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07793253.